Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Hepatitis Health Center

Font Size

FDA Approves Long-Acting Treatment for Hepatitis C

WebMD Health News

Jan. 22, 2001 (Washington) -- Federal health regulators on Monday approved the first long-acting treatment for the liver infection hepatitis C, offering at least some patients the option of an easier treatment regimen.

This means that patients with persistent, or chronic, infection can now have a once-weekly injection, instead of three times a week, at twice the effectiveness. And although there is still one other regimen out there that is considered the best option for many people, this new treatment has its advantages.

The most frightening thing about hepatitis C is its tendency to cause chronic liver disease. At least 75% of patients with acute hepatitis C ultimately develop a chronic infection, and most of these patients have accompanying persistent liver disease. Chronic hepatitis C can cause cirrhosis, liver failure, and liver cancer.

Two different regimens previously have been approved as therapy for hepatitis C in the U.S. -- therapy with interferon-alpha alone, which has anticancer properties, and also is effective in fighting viral infections, or combination therapy with interferon-alpha and ribavirin, which also is effective at treating some viral infections

The newly approved drug, Peg-Intron, is a once-a-week version of interferon-alpha.

But studies have indicated that the best therapy currently available for hepatitis C infection is the combination therapy.

The safety and effectiveness of Peg-Intron was demonstrated in a clinical trial involving about 1,200 adult patients, in which 24% of the study population responded to Peg-Intron treatment, compared to 12% of those patients on the interferon-alpha alone.

However, in a second trial involving about 1,700 patients, the combination therapy still proved best. Approximately 40% of the study population responded to the interferon-alpha and ribavirin vs. about 15% of those patients on interferon-alpha alone.

This FDA approval does not include approval of Peg-Intron for use in combination with ribavirin.

Still, the approval of Peg-Intron represents an important development, says Richard W. Zahn, president of Schering Laboratories, the maker of both Rebetron (the combination drug) and Peg-Intron.

Zahn explains that because patients can take the drug weekly, they may take it more readily and stick to treatment.

Today on WebMD

Hepatitus C virus
Types, symptoms and treatments.
liver illustration
Myths and facts about this essential organ.
woman eating apple
What you need to know.
doctor and patient
What causes it?
Hepatitis C Treatment
Syringes and graph illustration
liver illustration
passport, pills and vaccine
Scientist looking in microscope
Fatty Liver Disease
Digestive Diseases Liver Transplantation
Picture Of The Liver
Image Collection